Jeffrey Schriber, MD
Hematology & Oncology · Scottsdale, AZNPI 1851369821
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $520,933 of the $714,980 with a category attached, or 72.9%. It is spread thinly across 33 manufacturers, the largest accounting for just 15.7%. Reporting peaked in 2019 at $310,586 and has fallen 90.5% since, to $29,366 in 2025. Among hematology & oncology clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 618 payments — averaging $1156.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$113K
- Seagen Inc.$98K
- Beigene USA, Inc.$97K
- AstraZeneca$71K
- Astellas Pharma US Inc$48K
- Novartis$38K
- plus $250K from 27 others
Across 122 payments — averaging $16,322 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$1.2M
- CSL Behring$583K
- Astellas Pharma Global Development$95K
- Pharmacyclics LLC, An Abbvie Company$69K
- Janssen Research & Development, LLC$22K
- National Marrow Donor Program$10K
- plus $3K from 1 others
What the payments were for
- Consulting fees$123,87317%
- Speaking & faculty fees$520,93373%
- Travel & lodging$56,1458%
- Food & beverage$14,0302%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 71 | $112,559 |
| Seagen Inc. | 96 | $98,138 |
| Beigene USA, Inc. | 70 | $97,023 |
| AstraZeneca | 61 | $71,375 |
| Astellas Pharma US Inc | 34 | $48,034 |
| Novartis | 37 | $37,591 |
| Jazz Pharmaceuticals Inc. | 33 | $34,089 |
| Sanofi | 26 | $29,979 |
| Bristol Myers Squibb | 45 | $27,997 |
| Stemline Therapeutics Inc. | 18 | $27,749 |
| Agios Pharmaceuticals, Inc. | 27 | $25,528 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $21,890 |
| ADC Therapeutics America, Inc. | 10 | $17,435 |
| Beone Medicines USA, Inc. | 5 | $11,423 |
| CSL Behring | 1 | $8,125 |
| Karyopharm Therapeutics Inc. | 6 | $8,100 |
| Astellas Pharma Global Development | 7 | $7,201 |
| Janssen Scientific Affairs, LLC | 4 | $5,813 |
| Sanofi-aventis U.S. LLC | 3 | $5,154 |
| Gilead | 8 | $4,873 |
| Epizyme, Inc. | 5 | $4,100 |
| Servier Pharmaceuticals LLC | 2 | $3,319 |
| GSK | 2 | $3,274 |
| Ipsen Biopharmaceuticals, Inc | 2 | $2,310 |
| Johnson & Johnson | 7 | $1,332 |
| Incyte Corporation | 1 | $125 |
| Morphosys, US Inc. | 1 | $88 |
| Amgen | 4 | $86 |
| AbbVie | 4 | $83 |
| Pfizer | 4 | $76 |
| Merck | 4 | $63 |
| Secura Bio, Inc. | 1 | $23 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$714,980 in reported general payments places this provider in the 95th percentile of 261 hematology & oncology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PomalystPomalidomide | 15 | $341,874 |
| Lenalidomide | 27 | $336,686 |
| BrukinsaZanubrutinib | 19 | $291,516 |
| ScemblixAsciminib Hydrochloride | 19 | $213,355 |
| CalquenceAcalabrutinib Maleate | 12 | $185,373 |
| Acyclovir | 25 | $486 |
| Potassium Chloride | 15 | $477 |
| Fluconazole | 16 | $433 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 13 | $39 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Pomalyst | $112,559 | $341,87415 claims |
| Beigene USA, Inc.Brukinsa | $97,023 | $291,51619 claims |
| NovartisScemblix | $37,591 | $213,35519 claims |
| AstraZenecaCalquence | $71,375 | $185,37312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 261 hematology & oncology providers in Arizona.
Other hematology & oncology in Scottsdale
- Tanios Bekaii-SaabScottsdale$527K
- Rajesh KukunoorScottsdale$499K
- Yousef ZakhariaScottsdale$214K
- Thai HoScottsdale$190K
- Alan BryceScottsdale$157K
- Daniel AhnScottsdale$91K
- Brendan CurleyScottsdale$87K
- Alexander StewartScottsdale$76K
- Saurabh ChhabraScottsdale$68K
- Mitesh BoradScottsdale$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.